Saturday, May 25, 2013 Last update: 8:34 AM
Company Tech News as it Breaks
Trade Events
Celldex Therapeutics, Inc.
News articles for Celldex Therapeutics, Inc.:
Tuesday, December 11, 2012
- Celldex Therapeutics’ CDX-301 Safely Mobilizes Hematopoietic Cells in Phase 1 Study; Future Development PlannedCelldex Therapeutics, Inc. (NASDAQ: CLDX) announced positive results from a Phase 1 multi-dose study of CDX-301 (FMS-like tyrosine kinase-3 ligand) demonstrating that ... read more
Saturday, December 8, 2012
- Final Data from Celldex Therapeutic’s CDX-011 Phase 2 Study in Metastatic Breast Cancer Supports Overall Survival Benefit in Patients with High GPNMB ExpressionCelldex Therapeutics, Inc. (NASDAQ: CLDX) today announced final results from the Company’s randomized Phase 2b EMERGE study of CDX-011 in patients with ... read more
Friday, December 7, 2012
- Celldex Therapeutics Announces Upcoming Presentation at Oppenheimer Healthcare ConferenceCelldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present a corporate overview ... read more
Tuesday, December 4, 2012
- Celldex Therapeutics Announces Upcoming Data Presentations on CDX-1127 and CDX-011Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced upcoming data presentations on two of the Company’s fully human monoclonal antibody programs—CDX-1127 and CDX-011. ... read more
Friday, November 30, 2012
- Celldex Therapeutics Announces Upcoming Presentation at the Deutsche Bank 2012 dbAccess BioFESTCelldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present at the Deutsche ... read more